COMP <GO>
UTHR vs INSM // FREE CASH FLOW YIELD
United Therapeutics Corporation (NASDAQ) VS. Insmed Incorporated (NASDAQ) • 15-METRIC TALLY: UTHR 10
— INSM 2
▲ FREE CASH FLOW YIELD LEADER: UTHR
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
fcf-yield
4.09%
LAST: $112.58 (+0.89%) • MKT CAP: $24.37B
fcf-yield
-3.97%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. INSM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | INSM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 79.70% | +8.20 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | -35.00% | +55.10 | UTHR | /roic <GO> |
| EV/EBITDA & P/E Valuation | 12.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 4.09% | -3.97% | +8.06 | UTHR | /fcf-yield <GO> |
| Operating Margin | 46.90% | -60.00% | +106.90 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | -60.00% | +101.90 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 66.70% | -56.10 | INSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 5.25 | +17.27 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.9 | 61.0 | +5.90 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.03 | -0.08 | INSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 21.0x | -3.20 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.46B | $24.37B | $1.09B | UTHR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | INSM REV | UTHR GROSS % | INSM GROSS % | UTHR FCF | INSM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $606.4M | 87.9% | 79.7% | $1.04B | -$967.6M |
| FY 2024 | $2.88B | $363.7M | 89.2% | 76.4% | $1.08B | -$705.8M |
| FY 2023 | $2.33B | $305.2M | — | — | $873.3M | -$550.0M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
INSM // BETA 1.03